​

Inovio Pharmaceuticals (INO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

INO Stock Forecast

Inovio Pharmaceuticals (INO) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $22.67, with a high of $40.00 and a low of $8.00. This represents a 1202.87% increase from the last price of $1.74.

- $8 $16 $24 $32 $40 High: $40 Avg: $22.67 Low: $8 Last Closed Price: $1.74

INO Stock Rating

Inovio Pharmaceuticals stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (50.00%), 7 Hold (43.75%), 1 Sell (6.25%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 7 8 Strong Sell Sell Hold Buy Strong Buy

INO Price Target Upside V Benchmarks

TypeNameUpside
StockInovio Pharmaceuticals1202.87%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$22.67
Last Closing Price$1.74$1.74$1.74
Upside/Downside--1202.87%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25123--6
Mar, 25123--6
Feb, 25123--6
Jan, 25123--6
Dec, 24123--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 09, 2024Gregory RenzaRBC Capital$8.00$8.71-8.15%359.77%
May 14, 2024Hartaj SinghOppenheimer$40.00$11.45249.34%2198.85%
May 13, 2024Sudan LoganathanStephens$20.00$11.3676.06%1049.43%
Jan 25, 2024Hartaj SinghOppenheimer$4.00$6.79-41.09%129.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024OppenheimerOutperformOutperformhold
Oct 04, 2024OppenheimerUnderperformUnderperformhold
Aug 09, 2024RBC CapitalSector PerformSector Performhold
May 14, 2024OppenheimerOutperformOutperformhold
May 14, 2024H.C. WainwrightNeutralNeutralhold
May 13, 2024StephensOverweightinitialise
Jan 25, 2024OppenheimerOutperformupgrade

Financial Forecast

EPS Forecast

$-4K $-3K $-2K $-1K $-400 $500 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-16.64$-17.55$-14.47$-6.09$-3.95K----
Avg Forecast$-13.82$-15.00$-13.30$-6.10$-4.21$-2.92$-2.10$-1.57$-0.54
High Forecast$-3.42$-3.71$3.33$-5.35$-4.00$-1.75$-1.25$-0.34$0.14
Low Forecast$-24.21$-26.29$-29.98$-6.77$-4.49$-4.08$-3.41$-2.62$-1.22
Surprise %20.41%17.00%8.80%-0.16%93696.91%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.41M$1.77M$10.26M$832.01K-----
Avg Forecast$3.21M$3.33M$10.55M$1.06M$133.50K$3.12M$26.55M$78.50M$139.20M
High Forecast$5.07M$5.27M$20.74M$1.18M$166.88K$6.15M$26.56M$79.13M$274.60M
Low Forecast$1.35M$1.40M$404.28K$824.44K$111.25K$80.99K$26.54M$77.86M$3.62M
Surprise %130.77%-46.78%-2.75%-21.51%-----

Net Income Forecast

$-150B $-110B $-70B $-30B $10B $50B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-215.09M$-305.38M$-287.66M$-135.12M$-107.25B----
Avg Forecast$-306.33M$-332.61M$-294.82M$-135.12M$-94.16M$-64.62M$-51.66M$-56.67M$-11.97M
High Forecast$-75.78M$-82.28M$73.76M$-118.53M$-88.66M$-38.79M$-27.72M$-7.55M$3.19M
Low Forecast$-536.88M$-582.94M$-664.82M$-150.14M$-99.66M$-90.44M$-75.61M$-58.15M$-27.12M
Surprise %-29.79%-8.18%-2.43%-113805.24%----

INO Forecast FAQ

Is Inovio Pharmaceuticals stock a buy?

Inovio Pharmaceuticals stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 7 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Inovio Pharmaceuticals is a favorable investment for most analysts.

What is Inovio Pharmaceuticals's price target?

Inovio Pharmaceuticals's price target, set by 16 Wall Street analysts, averages $22.67 over the next 12 months. The price target range spans from $8 at the low end to $40 at the high end, suggesting a potential 1202.87% change from the previous closing price of $1.74.

How does Inovio Pharmaceuticals stock forecast compare to its benchmarks?

Inovio Pharmaceuticals's stock forecast shows a 1202.87% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Inovio Pharmaceuticals over the past three months?

  • April 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Inovio Pharmaceuticals’s EPS forecast?

Inovio Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.92, marking a -99.93% decrease from the reported $-3.949K in 2024. Estimates for the following years are $-2.1 in 2026, $-1.57 in 2027, and $-0.54 in 2028.

What is Inovio Pharmaceuticals’s revenue forecast?

Inovio Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $3.12M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $26.55M, followed by $78.5M for 2027, and $139.2M for 2028.

What is Inovio Pharmaceuticals’s net income forecast?

Inovio Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-64.616M, representing a -99.94% decrease from the reported $-107B in 2024. Projections indicate $-51.665M in 2026, $-56.675M in 2027, and $-11.974M in 2028.